Literature DB >> 22104307

M2 macrophage/microglial cells induce activation of Stat3 in primary central nervous system lymphoma.

Yoshihiro Komohara1, Hasita Horlad, Koji Ohnishi, Kazutaka Ohta, Keishi Makino, Hiroaki Hondo, Ryuya Yamanaka, Koji Kajiwara, Takafumi Saito, Jun-ichi Kuratsu, Motohiro Takeya.   

Abstract

Primary central nervous system lymphoma (PCNSL) is one of the most aggressive malignant lymphomas with a median survival of less than 20~40 months. Interest in signal transducer and activator of transcription 3 (Stat3) has increased during the past decade because Stat3 activation was found to contribute to tumor progression by inducing angiogenesis, immunosuppression, and metastasis. We previously demonstrated a significant correlation between Stat3 activation in tumor cells and infiltrating anti-inflammatory (M2) macrophages. Here, we focused on the phenotypes of infiltrating macrophages/microglial cells and Stat3 activation in PCNSL cells. The correlation of Stat3 activation or density of M2 macrophage infiltration with patient prognosis was also evaluated. We performed immunostaining for CD68, CD163, CD204, and pStat3 using paraffin-embedded PCNSL specimens obtained from 43 patients. CD163 and CD204 served as markers of the M2 phenotype. Dense infiltration of CD68(+) macrophages was found in all samples. High numbers of CD163(+) and CD204(+) M2 macrophages/microglial cells were observed in 29 and 25 cases, respectively. Stat3 activation in lymphoma cells was enhanced in the patients who showed denser infiltration of CD163(+) macrophages/microglial cells in tumor tissues. In vitro co-culture experiment to investigate cell-cell interactions between macrophages and lymphoma cells found that Stat3 in lymphoma cells was strongly activated by co-culture with macrophages. Numbers of CD68(+), CD163(+), and CD204(+) tumor-associated macrophages/microglial cells (TAMs) and Stat3 activation in lymphoma cells were not correlated with prognosis. However, because Stat3 involvement in tumor development was demonstrated in several malignant tumors, our present finding that cell-cell interactions of M2 macrophage/microglial cells with lymphoma cells induced Stat3 activation may provide novel insights into PCNSL pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22104307     DOI: 10.3960/jslrt.51.93

Source DB:  PubMed          Journal:  J Clin Exp Hematop        ISSN: 1346-4280


  25 in total

Review 1.  Prioritization schema for immunotherapy clinical trials in glioblastoma.

Authors:  Tiffany R Hodges; Sherise D Ferguson; Hillary G Caruso; Gary Kohanbash; Shouhao Zhou; Timothy F Cloughesy; Mitchel S Berger; George H Poste; Mustafa Khasraw; Sujuan Ba; Tao Jiang; Tom Mikkelson; W K Alfred Yung; John F de Groot; Howard Fine; Lewis C Cantley; Ingo K Mellinghoff; Duane A Mitchell; Hideho Okada; Amy B Heimberger
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

Review 2.  Microenvironment of adult T-cell leukemia/lymphoma-associated nodal lesions.

Authors:  Koichi Ohshima; Daisuke Niino; Kennosuke Karube
Journal:  Int J Hematol       Date:  2014-01-31       Impact factor: 2.490

3.  STAT3 activation is associated with cerebrospinal fluid interleukin-10 (IL-10) in primary central nervous system diffuse large B cell lymphoma.

Authors:  Takashi Mizowaki; Takashi Sasayama; Kazuhiro Tanaka; Katsu Mizukawa; Kumi Takata; Satoshi Nakamizo; Hirotomo Tanaka; Hiroaki Nagashima; Masamitsu Nishihara; Takanori Hirose; Tomoo Itoh; Eiji Kohmura
Journal:  J Neurooncol       Date:  2015-06-17       Impact factor: 4.130

4.  Stat3-positive tumor cells contribute to vessels neoformation in primary central nervous system lymphoma.

Authors:  Simona Ruggieri; Roberto Tamma; Nicoletta Resta; Francesco Albano; Nicoletta Coccaro; Daria Loconte; Tiziana Annese; Mariella Errede; Giorgina Specchia; Rebecca Senetta; Paola Cassoni; Domenico Ribatti; Beatrice Nico
Journal:  Oncotarget       Date:  2017-05-09

5.  CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma.

Authors:  Aurélien Viaccoz; François Ducray; Yannick Tholance; Gleicy Keli Barcelos; Laure Thomas-Maisonneuve; Hervé Ghesquières; David Meyronet; Isabelle Quadrio; Stéphanie Cartalat-Carel; Guy Louis-Tisserand; Emmanuel Jouanneau; Jacques Guyotat; Jérôme Honnorat; Armand Perret-Liaudet
Journal:  Neuro Oncol       Date:  2015-05-25       Impact factor: 12.300

6.  Clinicopathological risk factors for a poor prognosis of primary central nervous system lymphoma in elderly patients in the Tohoku and Niigata area: a multicenter, retrospective, cohort study of the Tohoku Brain Tumor Study Group.

Authors:  Kenichiro Asano; Yoji Yamashita; Takahiro Ono; Manabu Natsumeda; Takaaki Beppu; Kenichiro Matsuda; Masahiro Ichikawa; Masayuki Kanamori; Masashi Matsuzaka; Akira Kurose; Toshio Fumoto; Kiyoshi Saito; Yukihiko Sonoda; Kuniaki Ogasawara; Yukihiko Fujii; Hiroaki Shimizu; Hiroki Ohkuma; Chifumi Kitanaka; Takamasa Kayama; Teiji Tominaga
Journal:  Brain Tumor Pathol       Date:  2022-03-21       Impact factor: 3.298

7.  The adenosine-dependent angiogenic switch of macrophages to an M2-like phenotype is independent of interleukin-4 receptor alpha (IL-4Rα) signaling.

Authors:  Christopher James Ferrante; Grace Pinhal-Enfield; Genie Elson; Bruce Neil Cronstein; Gyorgy Hasko; Shalini Outram; Samuel Joseph Leibovich
Journal:  Inflammation       Date:  2013-08       Impact factor: 4.092

Review 8.  Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma.

Authors:  M Ponzoni; S Issa; T T Batchelor; J L Rubenstein
Journal:  Ann Oncol       Date:  2013-11-20       Impact factor: 32.976

9.  SN79, a sigma receptor ligand, blocks methamphetamine-induced microglial activation and cytokine upregulation.

Authors:  Matthew J Robson; Ryan C Turner; Zachary J Naser; Christopher R McCurdy; Jason D Huber; Rae R Matsumoto
Journal:  Exp Neurol       Date:  2013-04-28       Impact factor: 5.330

10.  Influence of Tumor Location on the Composition of Immune Infiltrate and Its Impact on Patient Survival. Lessons from DCBCL and Animal Models.

Authors:  Claire Galand; Sabrina Donnou; Thierry Jo Molina; Wolf Herman Fridman; Sylvain Fisson; Catherine Sautès-Fridman
Journal:  Front Immunol       Date:  2012-05-04       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.